1. The role of probiotic on protein energy wasting and micro-inflammation in peritoneal dialysis patients
Shuang CHEN ; Jing WU ; Jing-jing DA ; Yan RAN ; Yu-qi YANG ; Shu-wen QIE ; Yan ZHA
Chinese Journal of Practical Internal Medicine 2019;39(03):260-264
OBJECTIVE: To investigate the effect of probiotic on protein energy wasting and micro-inflammation in peritoneal dialysis patients. METHODS: One hundred and twelve patients who underwent peritoneal dialysis at the nephrology department of Guizhou provincial people's hospital in 2017, were randomly divided into intervention group(n=56) and control group(n=56), which were treated probiotic and placebo respectively two months, and collected biochemical, inflammatory, physical measurement and bioelectrical impedance index before and after treatment. RESULTS: The prevalence of protein-energy wasting was 64.29% and 60.71%in intervention group and control group, respectively. Compared with control group, patients in intervention group had lower urea nitrogen, triglyceride, low density lipoprotein, high-sensitivity C-reactive protein and interleukin-6 and higher serum albumin levels, and these differences were statistically significant(P<0.05). Physical measurement results showed that the upper arm muscle circumference of intervention group was increased compared to control group, and the change was statistically significant(P<0.05). Biological resistance testing results showed that the fat percentage of intervention group was significantly higher than that of control group(P<0.05).CONCLUSION: The treatment of probiotic could improve protein energy wasting and micro-inflammation in continuous peritoneal dialysis patients.
2.Cost-effectiveness of pharmaceutical smoking cessation intervention in China primary cancer prevention.
Pei Yuan SUN ; Yu Ting XIE ; Ran Ran QIE ; Huang HUANG ; Zhuo Lun HU ; Meng Yao WU ; Qi YAN ; Cai Rong ZHU ; Ju Fang SHI ; Kai Yong ZOU ; Ya Wei ZHANG
Chinese Journal of Oncology 2024;46(1):66-75
Objectives: To evaluate the cost-effectiveness of typical pharmaceutical smoking cessation intervention strategies in China in the context of primary cancer prevention. Methods: Markov cohort simulation models were established to simulate the burden of 12 smoking caused cancer, including lung cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, bladder cancer, cervical cancer, and acute myeloid leukemia. Taking incremental cost effectiveness ratio (ICER) as the main indicator, the model sets one year as the cycling period for 50 periods and simulates the cohort of 10 000 thirty-five-year-old current smokers with various smoking cessation strategies. To ensure the robustness of conclusion, univariate sensitivity analysis, probability sensitivity analysis, and age-group sensitivity analysis were conducted. Results: The results showed that varenicline intervention was the most cost-effective intervention. Compared to the next most effective option, incremental cost of each additional quality-adjusted life year is 11 140.28 yuan, which is below the threshold of willingness to pay (1 year GDP per capita). The value of ICER increased as the increasing age group of adopting intervention, but neither exceeded the threshold of willingness to pay. One-way sensitivity analysis showed that the value of discount rate, the hazard ratio and cost of intervention strategy had a greater impact on the result of ICER. Conclusion: In China, the use of varenicline to quit smoking is highly cost effective in the context of cancer primary prevention, especially for younger smokers.
Humans
;
Cost-Benefit Analysis
;
Smoking Cessation
;
Cost-Effectiveness Analysis
;
Nasopharyngeal Neoplasms
;
Varenicline
;
China
;
Kidney Neoplasms
;
Pharmaceutical Preparations
3.Cost-effectiveness of pharmaceutical smoking cessation intervention in China primary cancer prevention.
Pei Yuan SUN ; Yu Ting XIE ; Ran Ran QIE ; Huang HUANG ; Zhuo Lun HU ; Meng Yao WU ; Qi YAN ; Cai Rong ZHU ; Ju Fang SHI ; Kai Yong ZOU ; Ya Wei ZHANG
Chinese Journal of Oncology 2024;46(1):66-75
Objectives: To evaluate the cost-effectiveness of typical pharmaceutical smoking cessation intervention strategies in China in the context of primary cancer prevention. Methods: Markov cohort simulation models were established to simulate the burden of 12 smoking caused cancer, including lung cancer, oral cancer, nasopharyngeal cancer, laryngeal cancer, esophageal cancer, gastric cancer, pancreatic cancer, liver cancer, kidney cancer, bladder cancer, cervical cancer, and acute myeloid leukemia. Taking incremental cost effectiveness ratio (ICER) as the main indicator, the model sets one year as the cycling period for 50 periods and simulates the cohort of 10 000 thirty-five-year-old current smokers with various smoking cessation strategies. To ensure the robustness of conclusion, univariate sensitivity analysis, probability sensitivity analysis, and age-group sensitivity analysis were conducted. Results: The results showed that varenicline intervention was the most cost-effective intervention. Compared to the next most effective option, incremental cost of each additional quality-adjusted life year is 11 140.28 yuan, which is below the threshold of willingness to pay (1 year GDP per capita). The value of ICER increased as the increasing age group of adopting intervention, but neither exceeded the threshold of willingness to pay. One-way sensitivity analysis showed that the value of discount rate, the hazard ratio and cost of intervention strategy had a greater impact on the result of ICER. Conclusion: In China, the use of varenicline to quit smoking is highly cost effective in the context of cancer primary prevention, especially for younger smokers.
Humans
;
Cost-Benefit Analysis
;
Smoking Cessation
;
Cost-Effectiveness Analysis
;
Nasopharyngeal Neoplasms
;
Varenicline
;
China
;
Kidney Neoplasms
;
Pharmaceutical Preparations